ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

Slides:

Advertisements

Similar presentations

Monthly improvements in paid work productivity: ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) subpopulations (employed.

Advertisements

Monthly improvements in family, social and leisure activities to week 96 (last observation carried forward imputation). Assessed using the arthritis-specific.

Monthly improvements in paid work productivity: overall axial spondyloarthritis population (employed patients only; last observation carried forward imputation). Assessed.

PASI responder rates (A, B) and total resolution in (C) nail psoriasis, (D) enthesitis and (E) dactylitis in affected patients receiving CZP from Week.

Summary of TB cases across indications and trial periods

The genomic region spanning rs shows enhancer activity.

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Changes in evaluation indicators from baseline to 12 weeks per visit.

Example choice set: DAS28, 28 joint disease activity score; EUR, Euro; QALY, quality-adjusted life year. * In the choice sets, changes of the individual.

Percentage of patients achieving EULAR response

Baseline scores and corresponding changes to week 96 of the RAPID-axSpA trial for all CZP-treated patients included in the imaging substudy for: (A) SPARCC.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

Mean values of CANDEN spine inflammation score and for vertebral body and posterior elements subscores, bars represent the SEM; as observed (n=49, 47,

Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.

Patient disposition through 48 weeks in RA-BEYOND

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.

Frequency of patients in flare at each time point over 3 months

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

Univariate predictors of (A) ASDAS ID (<1

ACR responder rates in patients receiving CZP from Week 0, stratified by prior anti-TNF exposure (A−C) and the proportion of patients receiving CZP from.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

OR for selected baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by multivariate analysis of observed data. OR for selected baseline predictors.

Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.

Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.

Factors influencing the relationship between disease activity (as measured with the ASDAS) and radiographic progression (as measured with the 2-year mSASSS.

(A) Reduction of circulating stromal cell-derived factor (SDF)-1 levels over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis.

Serum levels of (A), C reactive protein (CRP), (B), erythrocyte sedimentation rate (ESR) and (C), calprotectin of cohort 1 (SPACE) with patients with early.

Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI.

Relationships between the baseline disease activity scores and scintigraphic sum scores for the patients with RA, pSpA and axSpA. Relationships between.

Different scenarios that explain the effect that an external factor (here occupational activity—blue collar vs white collar—used as an example) could hypothetically.

Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Clinical response in patients with early and established RA at month 24. *p

Least squares mean (LSM) changes from baseline in (A) Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total score and (B) Ankylosing.

ACR20 response rates. ACR20 response rates. ACR20 response rates based on non-responder imputation (NRI) for the 120/Q4W, 90/Q2W and placebo groups over.

Radiographic endpoints: (A) change from baseline in SHS at Week 52 and Week 104*†; (B) probability plots of change from baseline in SHS at Week 52 and.

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

Employment of patients with AS compared with controls, by BASDAI

ACR20/50/70 response rates at week 24 (TP1 per-protocol set).

ACR responses: (A) responses at Week 52 and Week 104

Characteristics of the included trials on non-pharmacological treatment. Characteristics of the included trials on non-pharmacological treatment. ASDAS,

Monthly improvements in home productivity: ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) subpopulations (last observation.

Subject disposition through week 156 of treatment

Patient disposition after 2 years of treatment.

Efficacy as first, second and third bDMARD in patients with axial spondyloarthritis. ASAS, Assessment of Spondylo Arthritis international Society; BASDAI,

Satisfaction with control of RA

Achievement of MDA over 144 weeks in patients initially receiving adalimumab or placebo during the double-blind period. Achievement of MDA over 144 weeks.

Classification tree with the selected characteristics.

(A) Mean (95% CI) change and (B) mean percentage (SE) change in enthesitis scores (Leeds Enthesitis Index, SPARCC Enthesitis Index, and MASES) from baseline.

(A) NKG2A and (B) NKG2C expression on NK cells in subjects with AS and HCs. The upper figure represents % of NK positive cells; the lower figure represents.

Follow-up and cause of anti-TNF-α discontinuation in 15 patients with rhupus. anti-TNF-α, antitumour necrosis factor alpha; ESR, erythrocyte sediment rate;

Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.

(A) Detailed comparison of the prevalence of single pathological lesions in both heel and knee in patients with SpA and non-SpA patients, as assessed by.

Kaplan-Meier estimate of drug continuation until discontinuation for tocilizumab, canakinumab, anakinra and etanercept, as a first biological agent for.

Forest plot showing the results of the meta-analysis on the effect of aerobic exercise on measured on VO2max in people with rheumatoid arthritis, spondyloarthritis.

Multivariable model of adjusted

Patient disposition. *Patients who switched multiple times were not included in this analysis; **for patients switching treatment regimens, discontinuations.

Graphical representation of the content of the Social Role Participation Questionnaire (SRPQ), which assesses several dimensions of role participation.

Percent of patients with ASDAS inactive disease grouped by normal or elevated CRP at baseline through week 156. §p

Improvement in BASDAI score in patients with normal or elevated CRP at baseline through week 156. *p

MRI remission in the imaging set of patients from the RAPID-axSpA trial. MRI remission in the imaging set of patients from the RAPID-axSpA trial. Remission.

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

(A) Percentage of patients achieving remission or response at week 12 or 24 after initiating ova therapy. (A) Percentage of patients achieving remission.

Distribution of points (%) across the ESSDAI domains in patients with neurological involvement and in those with non-neurological systemic involvement.

Presentation transcript:

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment visit (ie, final assessment 4 weeks after last study treatment) was considered as week 156. ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment visit (ie, final assessment 4 weeks after last study treatment) was considered as week 156. Data are shown as observed through week 156. ASAS 20/40, Assessment of Spondyloarthritis International Society criteria for 20%/40% improvement; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; n, number of subjects in the treatment group with evaluation at each time point. Helena Marzo-Ortega et al. RMD Open 2017;3:e000592 Copyright © BMJ Publishing Group & EULAR. All rights reserved.